AstraZeneca stops the eVOLVE-Lung02 lung cancer trial testing volrustomig in combination with other therapies, according to reports about the program’s status. The company is discontinuing the study, indicating that recruitment and further trial activity related to this protocol will not proceed.
The outlets frame the move as a trial discontinuation rather than a final decision on volrustomig’s overall development, with the focus specifically on the lung cancer study. While both reports reference the same trial activity, they use slightly different naming conventions for the program and its components, reflecting how each outlet describes the study’s title and trial designation.
The underlying context is that AstraZeneca is evaluating whether volrustomig—an investigational treatment—meets the clinical objectives in lung cancer settings. By pausing or ending this particular trial, the company adjusts its development pathway based on interim findings or other internal review processes, though the reports do not provide detailed outcome data in the information provided.
